同一主题业绩差高达50%： 申万菱信、永赢旗下部分医药基金缘何仍跌超10%|基金投资力测评

Core Insights - The medical theme funds have shown a strong recovery this year, with over 70% reporting positive returns, driven by the performance of the innovative drug sector [1][3] - There is a significant disparity in performance among medical theme funds, attributed to differences in stock selection and timing abilities of fund managers [2][7] Group 1: Fund Performance - As of April 14, 2023, 113 out of 277 medical theme funds had returns exceeding 10%, with notable performers like Zhongyin Hong Kong Stock Connect Medicine A and Ping An Medicine Selected A achieving returns of 36.03% and 35.83% respectively [3][4] - Conversely, some funds like Yongying Medicine Health C and Shenwan Lingshin Medicine Pioneer C reported negative returns of -12.82% and -10.24% [6][9] Group 2: Investment Strategy - Successful funds typically focus on high-growth sectors such as innovative drugs and medical technology, employing concentrated holdings and active management to achieve excess returns [8][10] - Fund managers who adapt their strategies in response to market changes tend to outperform those who do not, highlighting the importance of timely adjustments in investment approaches [7][10] Group 3: Market Trends - The innovative drug sector has been buoyed by policy support and industry growth, with the Hang Seng Innovative Drug Index rising nearly 32% in the first quarter [4][12] - Despite recent market volatility, some analysts believe the current innovative drug market trend is not over, citing stable growth in medical insurance revenue and favorable policy adjustments [12][14] Group 4: Challenges and Risks - The medical sector faces significant investment challenges due to frequent policy changes and intense competition, requiring fund managers to have strong research and analytical capabilities [10][15] - There is a caution against short-term speculative trading, emphasizing the need for a focus on fundamental growth potential in the innovative drug sector [15]